FDA approves first pill to prevent recurrent C. difficile infections

The Food and Drug Administration approved the first fecal microbiota product taken orally to prevent recurrent C. difficile infection.
“Today’s approval provides patients and healthcare providers a new way to help prevent recurrent C. difficile infection,” said Peter Marks, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “The availability of a fecal microbiota product that can be taken orally is a significant step forward in advancing patient care and accessibility for individuals who have experienced this disease that can be potentially life-threatening.”
Related News Articles
Headline
This season’s flu vaccines for the Southern Hemisphere have reduced the risk of being hospitalized for flu by 52%, based on mid-season data from five countries…
Headline
The Centers for Disease Control and Prevention alerted clinicians, laboratories and public health departments to recent fatal infections from Vibrio…
Headline
The Food and Drug Administration announced its approval of Pfizer’s Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use…
Chairperson's File
It’s been about 65 years since an effective vaccine was first used worldwide against poliomyelitis, or polio. Until then, polio was responsible for about 500,…
Headline
AHA this week released a resource on strategies and tactics that hospitals and health systems can adopt to prevent and control health care-associated…
Headline
The Centers for Disease Control and Prevention is investigating four locally acquired malaria cases in Florida and one in Texas, the first locally…